Lakeview Capital Partners LLC acquired a new stake in Seres Therapeutics Inc (NASDAQ:MCRB) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 34,163 shares of the biotechnology company’s stock, valued at approximately $346,000. Lakeview Capital Partners LLC owned approximately 0.08% of Seres Therapeutics at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of the company. California State Teachers Retirement System grew its holdings in Seres Therapeutics by 1.1% in the 2nd quarter. California State Teachers Retirement System now owns 36,280 shares of the biotechnology company’s stock valued at $410,000 after buying an additional 400 shares in the last quarter. Teachers Advisors LLC grew its holdings in Seres Therapeutics by 1.2% in the 2nd quarter. Teachers Advisors LLC now owns 38,758 shares of the biotechnology company’s stock valued at $438,000 after buying an additional 450 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Seres Therapeutics by 0.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 91,543 shares of the biotechnology company’s stock valued at $1,035,000 after buying an additional 494 shares in the last quarter. Parametric Portfolio Associates LLC grew its holdings in Seres Therapeutics by 2.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 21,915 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 580 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Seres Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,270 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 2,410 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.
Several equities analysts recently issued reports on the company. Zacks Investment Research lowered Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. BidaskClub lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, February 7th. Three analysts have rated the stock with a sell rating and nine have given a buy rating to the stock. Seres Therapeutics has a consensus rating of “Buy” and a consensus price target of $18.00.
Seres Therapeutics Inc (MCRB) traded up $0.23 during trading hours on Tuesday, reaching $8.68. The company had a trading volume of 260,100 shares, compared to its average volume of 147,054. The stock has a market cap of $342.48, a P/E ratio of -4.09 and a beta of 0.24. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.11. Seres Therapeutics Inc has a 12-month low of $7.90 and a 12-month high of $17.42.
COPYRIGHT VIOLATION NOTICE: “Lakeview Capital Partners LLC Takes Position in Seres Therapeutics Inc (MCRB)” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://ledgergazette.com/2018/02/13/lakeview-capital-partners-llc-takes-position-in-seres-therapeutics-inc-mcrb.html.
Seres Therapeutics Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.